Jazz Pharmaceuticals (JAZZ) Receivables (2010 - 2026)

Jazz Pharmaceuticals has reported Receivables for 17 years, with the latest figure at $836.3 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 28.07% year-over-year to $836.3 million; the trailing twelve-month figure through Mar 2026 stood at $836.3 million (up 28.07% YoY), and the FY2025 full-year result was $830.7 million, up 15.9% from the prior year.
• Receivables for Q1 2026 stood at $836.3 million, up from $830.7 million in the prior quarter.
• The five-year high for Receivables was $836.3 million in Q1 2026, with the low at $572.4 million in Q1 2022.
• Average Receivables over 5 years is $684.2 million, with a median of $698.0 million recorded in 2024.
• Year-over-year, Receivables surged 38.27% in 2022 and dropped 7.65% in 2025.
• Tracing JAZZ's Receivables over 5 years: stood at $651.5 million in 2022, then grew by 8.33% to $705.8 million in 2023, then climbed by 1.55% to $716.8 million in 2024, then grew by 15.9% to $830.7 million in 2025, then climbed by 0.67% to $836.3 million in 2026.
• The last three Receivables figures came in at $836.3 million (Q1 2026), $830.7 million (Q4 2025), and $764.4 million (Q3 2025), per Business Quant data.

Peer Comparison